Alpha Cognition Inc.
ACOG Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2023–FY2025
Last close · Oct 23, 2026
$8.34
0.4%What Alpha Cognition Inc. does
No business description yet.
- Legal name
- Alpha Cognition Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Accession · CIK
- 0001213900-26-037614
0001655923
Revenue and margins
Alpha Cognition Inc. had $10.2M of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$20.7M in fiscal 2025, −202.3% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Alpha Cognition Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 144.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably Alpha Cognition Inc. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $1.4M | $48.5M | $66.0M |
| Interest coverage | −567.9x | −114.1x | — |
| Current ratio | 0.7x | 15.0x | 8.7x |
| Quick ratio | 0.7x | 14.8x | 8.1x |
| Total assets | $2.5M | $50.7M | $79.7M |
| Total liabilities | $7.2M | $11.6M | $17.2M |
| Shareholders' equity | −$4.7M | $39.1M | $62.5M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✓ | ✕ |
| Share count didn't rise | — | ✕ | ✕ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 6 | — / 6 |
| Accruals ratio | −202.4% | −26.4% | −0.4% |
| Altman Z'' | −111.75 | 3.09 | 3.69 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | $10.2M |
| Provision for credit losses | — | $0.1M | — |
| Gross profit | — | — | $9.6M |
| Research and development | $4.9M | $3.9M | $1.9M |
| Operating income | −$9.9M | −$12.0M | −$22.7M |
| Interest expense | $0.0M | $0.1M | — |
| Pretax income | — | −$0.6M | −$9.3M |
| Net income | −$13.8M | −$14.8M | −$20.7M |
| Net income to common | −$13.8M | −$14.8M | −$20.7M |
| Diluted EPS | −$3.84 | −$2.04 | −$1.18 |
| Diluted shares | 0.00B | 0.01B | 0.02B |
| Cash flow | |||
| Cash from operations | −$8.8M | −$7.8M | −$20.4M |
| Capital expenditure | — | $0.0M | $0.3M |
| Free cash flow | — | −$7.8M | −$20.7M |
| Depreciation and amortization | $0.1M | $0.1M | $0.1M |
| Stock-based compensation | $2.4M | $1.1M | $4.9M |
| Balance sheet | |||
| Cash and short-term investments | $1.4M | $48.5M | $66.0M |
| Current assets | $1.9M | $50.3M | $79.0M |
| Current liabilities | $2.6M | $3.4M | $9.1M |
| Inventory | — | $0.6M | $5.1M |
| Property and equipment, net | $0.0M | $0.0M | $0.3M |
| Intangible assets | $0.5M | $0.4M | $0.4M |
| Total assets | $2.5M | $50.7M | $79.7M |
| Total liabilities | $7.2M | $11.6M | $17.2M |
| Preferred stock | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | −$4.7M | $39.1M | $62.5M |
| Margins | |||
| Gross margin | — | — | 94.1% |
| Operating margin | — | — | −221.7% |
| EBITDA margin | — | — | −221.1% |
| Net margin | — | — | −202.2% |
| FCF margin | — | — | −202.3% |
| Returns | |||
| Return on capital employed | 6,067.2% | −25.4% | −32.1% |
| Return on equity | — | −86.0% | −40.7% |
| Return on assets | −561.3% | −55.6% | −31.7% |
| Return on tangible equity | — | −38.2% | −33.3% |
| Growth | |||
| Share count change | — | 102.2% | 144.0% |
| Financial health | |||
| Interest coverage | −567.9x | −114.1x | — |
| Current ratio | 0.7x | 15.0x | 8.7x |
| Quick ratio | 0.7x | 14.8x | 8.1x |
| Capital allocation | |||
| Capex / revenue | — | — | 2.9% |
| Stock comp / revenue | — | — | 48.2% |
| Quality scores | |||
| Altman Z'' | −111.7 | 3.1 | 3.7 |
| Accruals ratio | −202.4% | −26.4% | −0.4% |
Source: SEC EDGAR XBRL filings (CIK 0001655923). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.
